PMA supplement
P130020 S004: Senographe Pristina 3D and SenoClaire
FDA PMA supplement · Normal 180 Day Track · GE Healthcare
Key facts
| Original PMA | P130020 |
|---|---|
| Supplement number | S004 |
| Supplement type | Normal 180 Day Track |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | Senographe Pristina 3D and SenoClaire |
| Generic name | Digital breast tomosynthesis |
| Applicant | GE Healthcare |
| Product code | OTE |
| Received date | May 4, 2020 |
| Decision date | Mar 23, 2021 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: